Eli lilly and company (LLY)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Cash Flows from Operating Activities
Net Income (Loss) Attributable to Parent

1,456

1,495

1,253

1,327

4,241

1,125

1,149

-259

1,217

-1,656

555

1,008

-110

771

778

747

440

478

799

600

529

428

500

733

727

727

1,203

1,206

1,548

827

1,326

923

1,011

858

1,236

1,197

1,055

1,169

1,302

1,348

1,248

915

941

1,158

1,313

Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Gain (Loss) on Disposition of Business

0

-

0

0

3,680

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

273

340

288

247

356

345

415

425

422

411

372

395

386

344

392

373

385

343

358

368

357

339

342

348

348

351

349

363

381

344

369

362

385

318

358

355

340

338

344

345

299

375

1,534

-306

-306

Change in deferred income taxes

-11

-85

12

-61

72

-165

-26

-157

22

939

143

-166

-128

-88

-519

138

30

1,419

-4

-559

-107

-188

30

51

70

-1,073

608

249

-51

-332

55

282

-132

490

-207

78

-92

-79

-162

-86

-230

-496

-33

211

129

Stock-based compensation expense

71

81

75

79

75

72

68

70

68

72

69

69

69

66

61

65

62

58

54

55

48

40

38

38

38

39

36

33

35

41

34

34

30

36

36

36

37

55

47

54

73

104

424

-94

-66

Acquired in-process research and development (Note 3)

52

0

77

25

136

330

25

1,624

0

47

205

0

857

30

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

252

0

0

0

32

58

0

0

0

Income related to termination of the exenatide collaboration with Amylin

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

495

0

787

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from (payments for) terminations of interest rate swaps

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-20

206

-88

-259

0

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other changes in operating assets and liabilities, net of acquisitions and divestitures

1,408

-

247

802

714

-

-293

662

1,270

-

-593

123

995

-

2,407

86

-1,382

-

-75

25

-913

-

473

-103

-917

-

-226

-223

-1,048

-

488

-1,458

698

-

-166

-506

595

-

-116

111

-815

-

-573

-522

-672

Net marketing investigation charges accrued paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24

-56

-128

207

-329

-1,063

Other non-cash operating activities, net

-74

193

74

113

-32

151

137

162

21

75

227

134

3

77

61

-8

245

-16

-27

356

-49

331

-48

-14

12

-42

20

37

9

110

57

28

-8

49

-82

22

-7

-50

-61

-11

-54

726

-349

-6

-8

Other changes in operating assets and liabilities, net of acquisitions and divestitures:
Net Cash Provided by Operating Activities

382

1,963

1,510

1,051

311

1,448

2,121

1,517

436

1,743

1,881

1,651

339

2,006

1,661

1,401

-219

996

1,104

948

-84

1,440

1,691

1,053

272

1,726

1,991

1,637

379

1,602

1,544

1,306

852

1,944

2,073

2,040

1,176

2,228

1,759

1,911

958

2,018

1,305

923

87

Cash Flows from Investing Activities
Net purchases of property and equipment

258

326

263

240

203

394

269

310

236

443

242

221

169

409

227

245

154

380

273

223

188

408

296

254

202

464

253

136

157

413

182

179

130

255

175

139

101

250

164

154

125

256

174

176

157

Cash released for pending acquisition (Note 3)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-5,405

5,405

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales and maturities of short-term investments

36

20

26

53

35

17

38

2,046

450

2,532

642

509

1,168

396

320

403

521

576

300

778

507

1,392

771

722

1,166

942

396

374

1,607

421

740

314

1,070

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of short-term investments

0

8

0

0

33

0

0

0

112

415

1,090

1,594

289

901

160

166

98

78

175

422

165

236

597

401

402

752

263

202

313

303

1,091

163

612

2,603

-26

20

-539

485

198

1

0

164

-105

-171

-286

Proceeds from sales of noncurrent investments

54

111

82

332

83

64

49

3,084

310

899

579

579

528

479

687

580

338

796

521

1,154

596

3,653

1,815

2,906

2,633

2,752

3,019

3,364

2,098

798

1,106

1,028

1,423

1,055

647

223

211

140

61

192

191

365

374

182

184

Purchases of noncurrent investments

83

50

50

86

60

118

43

114

561

872

1,380

1,412

945

705

1,371

1,552

716

553

840

908

924

1,166

3,042

2,824

2,770

3,802

3,763

4,614

1,861

2,111

2,030

1,320

2,156

1,800

1,023

1,397

238

549

266

195

57

103

206

55

67

Proceeds from sale of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

410

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24

0

0

0

36

34

34

33

27

172

403

29

23

19

400

0

-

-

-

-

Purchases of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-80

-256

190

-95

0

0

-

-

-

-

-

-

-

-

-

-

-

-388

-

0

0

-50

-90

0

0

0

Cash paid for acquisitions, net of cash acquired (Note 3)

849

0

0

0

6,917

0

0

0

0

0

0

0

882

0

0

45

0

-4

11

0

5,276

0

0

551

0

-

-

-

-

0

0

3

195

0

307

0

0

-

-

-

-

-

-

-

-

Purchases of in-process research and development

13

0

77

45

196

229

30

1,548

0

50

205

0

831

-

0

0

0

-

50

136

200

-

45

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other investing activities, net

-51

-232

141

-46

385

-1

143

24

21

-2

61

109

7

55

43

-4

36

30

41

59

2

-334

255

65

36

5

35

37

18

-126

18

26

17

78

1

-2

34

139

22

46

10

23

31

20

19

Net Cash Used for Investing Activities

-1,060

-41

-423

61

-7,678

-659

-398

3,133

-170

1,652

-1,758

-2,248

-1,429

-1,178

-794

-1,020

-145

253

-570

182

160

-2,178

-1,649

-468

388

-1,232

-943

-1,251

1,355

-1,662

-132

-385

-652

-1,876

-1,008

-1,898

-40

-1,564

-788

-754

-52

-254

67

102

227

Cash Flows from Financing Activities
Dividends paid

671

587

587

598

637

572

572

579

587

548

547

548

547

541

537

541

538

533

526

539

527

525

525

526

524

528

527

533

531

548

544

550

544

543

540

552

543

544

545

536

539

539

536

539

536

Net change in short-term borrowings

1,748

-63

-505

-286

1,850

-4,495

2,545

953

-1,202

170

1,101

-371

497

1,294

-0

-0

-1

0

-1

-590

-2,088

2,375

302

2

0

-

-

-

-

6

0

-1

-5

-105

99

-12

-116

0

126

6

-7

-994

-16

-569

-4,243

Proceeds from issuance of long-term debt

0

2,108

0

0

4,448

0

2,477

0

0

-

-

-

-

-

-

-

-

0

0

2,272

2,182

0

0

0

992

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,400

Repayments of long-term debt

276

2,266

0

0

600

7

0

201

800

0

0

0

630

0

0

0

0

-

-

-

-

0

0

31

1,002

7

1

0

0

2

0

0

1,507

7

0

0

54

0

1

-0

0

-

-

-

-

Purchases of common stock

500

300

600

0

3,500

1,100

1,000

950

1,100

99

0

199

0

300

0

0

300

252

61

124

310

300

300

145

55

500

0

0

1,198

721

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Other financing activities, net

-194

-4

0

-1

-193

-58

-83

-54

-176

-64

-52

-51

-195

-68

-61

-85

-84

-80

-5

-11

43

-12

117

-1

-6

0

0

0

0

-

-

-

-

5

0

0

0

-4

25

-2

0

-

-

-

-

Net Cash Provided by Financing Activities

106

-1,113

-1,692

-885

1,367

-1,639

432

-831

-3,866

-542

500

1,059

-875

385

-600

579

-924

-871

-595

-943

-701

1,537

-405

-702

-595

-1,036

-529

-533

-1,730

-1,265

-544

-552

-2,057

-650

-440

-564

-713

-549

-393

-531

-547

-1,128

-913

-1,111

-2,380

Effect of exchange rate changes on cash and cash equivalents

-66

-35

-119

27

37

-111

-13

-86

148

-42

30

-9

0

-120

-15

-29

-70

49

-16

62

-181

-93

-235

-4

-7

3

63

-1

-86

25

106

-144

56

-92

-140

29

91

-29

168

-187

-96

-21

65

95

-118

Net decrease in cash and cash equivalents

-638

773

-726

253

-5,961

-961

2,142

3,733

-3,451

2,811

654

453

-1,965

1,093

251

930

-1,358

427

-76

250

-806

705

-599

-122

57

-538

582

-150

-82

-1,300

973

223

-1,800

-675

484

-392

513

84

745

438

262

614

525

9

-2,183